The NRS has announced four new grants for ongoing research into the knowledge, cause and treatment of rosacea.
Dr. Gallo, Dr. Granstein and Dr. Steinhoff have been awarded grants to continue their existing NRS-funded research while Dr. Helfrich has been awarded a grant for new areas of funding.
Briefly, (for full details, see the NRS Blog):
- Dr. Richard Gallo, chief of the division of dermatology at the University of California – San Diego, and Dr. Kenshi Yamasaki of the Veterans Medical Research Foundation were awarded $25,000 to continue their NRS-funded research of how cathelicidins may play a role in the development of subtype 2 (papulopustular) rosacea.
- Dr. Richard Granstein, chairman of dermatology at Cornell University, and colleagues were awarded $25,000 to continue their research on the role of adenosine triphosphate (ATP) in recruiting inflammatory cells in subtype 2 rosacea.
- Dr. Yolanda Helfrich, assistant professor of dermatology at the University of Michigan, was awarded $25,000 to compare subtype 1 (erythematotelangiectatic) rosacea and photoaging, both of which may include the development of telangiectasia (visible blood vessels) and erythema (redness).
- Dr. Martin Steinhoff, department of dermatology, University of Muenster, Germany, was awarded $25,000 to study the role of neuroimmune interactions in the pathophysiology of rosacea.
